Suramin Hexasodium Salt

• CAT Number: I001130
• CAS Number: 129-46-4
• Molecular Formula: C₅₁H₃₄N₆Na₆O₂₃S₆
• Molecular Weight: 1429.15
• Purity: ≥95%
• Synonyms: sodium 8,8/’-((3,3/’-((3,3/’-(carbonylbis(azanediyl))bis(benzoyl))bis(azanediyl))bis(4-methylbenzoyl))bis(azanediyl))bis(naphthalene-1,3,5-trisulfonate)
• Target: P2X purinergic receptor
• Solubility: H2O: > 10 mg/mL， DMSO：< 6 mg/mL
• Storage: 0-6°C
• IUPAC Name: hexasodium;8-[[4-methyl-3-[[3-[[3-[[2-methyl-5-[(4,6,8-trisulfonatonaphthalen-1-yl)carbamoyl]phenyl]carbamoyl]phenyl]carbamoylamino]benzoyl]amino]benzoyl]amino]naphthalene-1,3,5-trisulfonate
• InChI: InChI=1S/C51H40N6O23S6.6Na/c1-25-9-11-29(49(60)54-37-13-15-41(83(69,70)71)35-21-33(81(63,64)65)23-43(45(35)37)85(75,76)77)19-39(25)56-47(58)27-5-3-7-31(17-27)52-51(62)53-32-8-4-6-28(18-32)48(59)57-40-20-30(12-10-26(40)2)50(61)55-38-14-16-42(84(72,73)74)36-22-34(82(66,67)68)24-44(46(36)38)86(78,79)80;;;;;;/h3-24H,1-2H3,(H,54,60)(H,55,61)(H,56,58)(H,57,59)(H2,52,53,62)(H,63,64,65)(H,66,67,68)(H,69,70,71)(H,72,73,74)(H,75,76,77)(H,78,79,80);;;;;;/q;6*+1/p-6
• InChIKey: VAPNKLKDKUDFHK-UHFFFAOYSA-H
• SMILES: CC1=C(C=C(C=C1)C(=O)NC2=C3C(=CC(=CC3=C(C=C2)S(=O)(=O)[O-])S(=O)(=O)[O-])S(=O)(=O)[O-])NC(=O)C4=CC(=CC=C4)NC(=O)NC5=CC=CC(=C5)C(=O)NC6=C(C=CC(=C6)C(=O)NC7=C8C(=CC(=CC8=C(C=C7)S(=O)(=O)[O-])S(=O)(=O)[O-])S(=O)(=O)[O-])C.[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]

Suramin hexasodium salt（Cat No.:I001130）, is a derivative of suramin, a medication utilized for treating certain parasitic infections and as an antineoplastic agent. It is a water-soluble form of suramin, facilitating its handling and administration. This polyanionic compound exhibits a range of pharmacological activities, including antiparasitic, antiviral, and antineoplastic effects. Suramin hexasodium salt finds application primarily in research environments for in vitro studies and experimental therapies targeting diseases such as cancer, viral infections, and inflammatory disorders.

Reference

[1]. Klinger M, et al. Suramin and the suramin analogue NF307 discriminate among calmodulin-binding sites. Biochem J. 2001 May 1;355(Pt 3):827-33.
[2]. Charlton SJ, et al. PPADS and suramin as antagonists at cloned P2Y- and P2U-purinoceptors. Br J Pharmacol. 1996 Jun;118(3):704-10.
[3]. Eisenberger MA, et al. Suramin. Cancer Treat Rev. 1994 Jul;20(3):259-73.
[4]. Stein CA. Suramin: a novel antineoplastic agent with multiple potential mechanisms of action. Cancer Res. 1993 May 15;53(10 Suppl):2239-48.
[5]. McGeary RP, et al. Suramin: clinical uses and structure-activity relationships. Mini Rev Med Chem. 2008 Nov;8(13):1384-94.